Meropenem Panpharma (Meropenem Trihydrate)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This disruption leads to loss of cell‑wall integrity and bacterial cell death, providing a bactericidal effect against a broad range of Gram‑negative, Gram‑positive, and anaerobic organisms.

The dose of Meropenem Panpharma is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, weight, and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Safety data for Meropenem in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meropenem offers a broad spectrum of activity similar to other carbapenems such as imipenem‑cilastatin, but it is less likely to cause nephrotoxicity and does not require co‑administration of a renal protective agent. Its stability against many β‑lactamases makes it a preferred option for multidrug‑resistant infections.

Meropenem Panpharma should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under the same temperature conditions.

The product is supplied as a sterile powder for injection. It is reconstituted with the appropriate diluent and administered intravenously, typically as a short infusion over 15‑30 minutes. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious adverse events include seizures, especially in patients with pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant renal or hepatic toxicity. Prompt recognition and discontinuation are essential if these events occur.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving valproic acid, where alternative therapy may be preferred.